[House Report 119-382]
[From the U.S. Government Publishing Office]
119th Congress } { Report
HOUSE OF REPRESENTATIVES
1st Session } { 119-382
======================================================================
WOMEN AND LUNG CANCER RESEARCH AND PREVENTIVE S
ERVICES ACT OF 2025
_______
November 18, 2025.--Committed to the Committee of the Whole House on
the State of the Union and ordered to be printed
_______
Mr. Guthrie, from the Committee on Energy and Commerce, submitted the
following
R E P O R T
[To accompany H.R. 2319]
The Committee on Energy and Commerce, to whom was referred
the bill (H.R. 2319) to direct the Secretary of Health and
Human Services to conduct a review to evaluate the status of
research on lung cancer in women and underserved populations,
and for other purposes, having considered the same, reports
favorably thereon without amendment and recommends that the
bill do pass.
CONTENTS
Page
Purpose and Summary.............................................. 2
Background and Need for Legislation.............................. 2
Committee Action................................................. 2
Committee Votes.................................................. 3
Oversight Findings and Recommendations........................... 6
New Budget Authority, Entitlement Authority, and Tax Expenditures 6
Congressional Budget Office Estimate............................. 6
Federal Mandates Statement....................................... 6
Statement of General Performance Goals and Objectives............ 6
Duplication of Federal Programs.................................. 6
Related Committee and Subcommittee Hearings...................... 6
Committee Cost Estimate.......................................... 7
Earmark, Limited Tax Benefits, and Limited Tariff Benefits....... 7
Advisory Committee Statement..................................... 7
Applicability to Legislative Branch.............................. 7
Section-by-Section Analysis of the Legislation................... 7
Changes in Existing Law Made by the Bill, as Reported............ 8
PURPOSE AND SUMMARY
H.R. 2319, Women and Lung Cancer Research and Preventive
Services Act of 2025, requires the Department of Health and
Human Services (HHS) to conduct an interagency review on the
status of, and identify research related to, women and
underserved populations with lung cancer. The review would
include assessments of current research and access to
prevention services, the availability of research opportunities
regarding prevention, detection, and treatment, and
recommendations for national public education and screening
strategies.
BACKGROUND AND NEED FOR LEGISLATION
Lung cancer is the third most common cancer in the United
States.\1\ Worldwide, over 600,000 women die of lung cancer
each year.\2\ About 10 to 20 percent of lung cancers, or 20,000
to 40,000 lung cancers each year, happen in people who never
smoked or smoked fewer than 100 cigarettes in their
lifetime.\3\ A better understanding of additional risk factors
beyond smoking cigarettes is needed for more effective
screening, diagnosis, treatment, and public health strategies,
particularly around women and underserved populations.
---------------------------------------------------------------------------
\1\Lung Cancer Statistics, U.S. Centers for Disease Control and
Prevention (Jun. 13, 2024), https://www.cdc.gov/lung-cancer/statistics/
?CDC_AAref_Val=https://www.cdc.gov/cancer/lung/statistics/index.htm.
\2\Women and Lung Cancer, Lung Cancer Research Foundation, https://
www.lungcancer
researchfoundation.org/for-patients/women-and-lc/.
\3\Lung Cancer Among People Who Never Smoked, U.S. Centers for
Disease Control and Prevention (Dec. 4, 2023), https://www.cdc.gov/
lung-cancer/nonsmokers/index.html#::text=
cancer%2C%20and%20asbestos.-
,In%20the%20United%20States%2C%20about%2010%25%20to%
2020%25%20of,2%2C900%20of%20these%20lung%20cancers.
---------------------------------------------------------------------------
H.R. 2319 would help advance both existing research and
emerging opportunities needed to reduce lung cancer mortality--
especially among women, who face unique risks and outcomes. The
bipartisan legislation will provide a complete review of the
research by requiring an interagency review by HHS, working
with the Departments of Defense and Veterans Affairs, to
evaluate the status and identify opportunities for research on
women and lung cancer, including access to preventative
services, strategic public awareness and education campaigns on
lung cancer.
COMMITTEE ACTION
On February 14, 2024, the Subcommittee on Health held a
hearing on H.R. 4534.\4\ The title of the hearing was
``Legislative Proposals to Support Patients and Caregivers.''
The Subcommittee received testimony from:
---------------------------------------------------------------------------
\4\Provisions of H.R. 4534 were reintroduced in the 119th Congress
as H.R. 2319.
---------------------------------------------------------------------------
Andy Shih, PhD, Chief Science Officer,
Autism Speaks;
Corey Feist, JD, MBA, Co-Founder and CEO,
Dr. Lorna Breen Heroes' Foundation;
Joanne Pike, DrPH, President and CEO,
Alzheimer's Association;
Gordon Tomaselli, MD, Former President,
American Heart Association; Marilyn and Stanley M. Katz
Dean, Emeritus and Professor of Medicine, Albert
Einstein College of Medicine; Adjunct Professor of
Medicine, Johns Hopkins University School of Medicine;
Michelle Whitten, President, CEO, and Co-
Founder, Global Down Syndrome Foundation;
Randy Strozyk, President, American Ambulance
Association; and
Christina Annunziata, MD, PhD, Senior Vice
President of Extramural Discovery Science, American
Cancer Society.
On May 16, 2024, the Subcommittee on Health met in open
markup session and forwarded H.R. 4534, as amended, to the full
Committee by a record vote of 21 yeas to 0 nays.
On June 12, 2024, the full Committee on Energy and Commerce
met in open markup session and ordered H.R. 4534, as amended,
favorably reported to the House by a record vote of 44 yeas and
0 nays.
On April 29, 2025, the full Committee on Energy and
Commerce met in open markup session and ordered H.R. 2319
favorably reported to the House by a voice vote.
COMMITTEE VOTES
Clause 3(b) of rule XIII requires the Committee to list the
record votes on the motion to report legislation and amendments
thereto. The following reflects the record votes taken during
the Committee consideration:
OVERSIGHT FINDINGS AND RECOMMENDATIONS
Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of
rule XIII, the Committee held a hearing and made findings that
are reflected in this report.
NEW BUDGET AUTHORITY, ENTITLEMENT AUTHORITY,
AND TAX EXPENDITURES
Pursuant to clause 3(c)(2) of rule XIII, the Committee
finds that H.R. 2319 would result in no new or increased budget
authority, entitlement authority, or tax expenditures or
revenues.
CONGRESSIONAL BUDGET OFFICE ESTIMATE
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
FEDERAL MANDATES STATEMENT
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
STATEMENT OF GENERAL PERFORMANCE GOALS AND OBJECTIVES
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to review,
evaluate the status of, and identify research and educational
opportunities related to lung cancer in women and certain
underserved populations.
DUPLICATION OF FEDERAL PROGRAMS
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 2319 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
RELATED COMMITTEE AND SUBCOMMITTEE HEARINGS
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 2319:
On February 14, 2024, the Subcommittee on
Health held a hearing on H.R. 4534.\5\ The title of the
hearing was ``Legislative Proposals to Support Patients
and Caregivers.'' The Subcommittee received testimony
from:
---------------------------------------------------------------------------
\5\Provisions of H.R. 4534 were reintroduced in the 119th Congress
as H.R. 2319.
---------------------------------------------------------------------------
Andy Shih, PhD, Chief Science
Officer, Autism Speaks;
Corey Feist, JD, MBA, Co-Founder
and CEO, Dr. Lorna Breen Heroes' Foundation;
Joanne Pike, DrPH, President and
CEO, Alzheimer's Association;
Gordon Tomaselli, MD, Former
President, American Heart Association; Marilyn
and Stanley M. Katz Dean, Emeritus and
Professor of Medicine, Albert Einstein College
of Medicine; Adjunct Professor of Medicine,
Johns Hopkins University School of Medicine;
Michelle Whitten, President,
CEO, and Co-Founder, Global Down Syndrome
Foundation;
Randy Strozyk, President,
American Ambulance Association; and
Christina Annunziata, MD, PhD,
Senior Vice President of Extramural Discovery
Science, American Cancer Society.
COMMITTEE COST ESTIMATE
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
EARMARK, LIMITED TAX BENEFITS, AND LIMITED TARIFF BENEFITS
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 2319 contains no earmarks, limited
tax benefits, or limited tariff benefits.
ADVISORY COMMITTEE STATEMENT
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
APPLICABILITY TO LEGISLATIVE BRANCH
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
SECTION-BY-SECTION ANALYSIS OF THE LEGISLATION
Section 1. Short title
Section 1 provides that the Act may be cited as the ``Women
and Lung Cancer Research and Preventative Services Act of
2025''.
Section 2. Interagency review to evaluate and identify opportunities
for the acceleration of research on lung cancer in women and
underserved populations, greater access to preventative
services, and strategic public awareness and education
campaigns
Section 2 requires the Secretary of Health and Human
Services (HHS), in consultation with the Secretary of Defense
and Secretary of Veteran Affairs, to conduct an interagency
review on the status of, and identify research and education
opportunities related to, women and underserved populations
with lung cancer. The review shall include assessments of
current research and access to prevention services, the
availability of research opportunities regarding prevention,
detection, and treatment, and recommendations for national
public education and screening strategies. This section also
requires the Secretary of HHS to submit a report to Congress
detailing the results of the review within two years of
enactment.
CHANGES IN EXISTING LAW MADE BY THE BILL, AS REPORTED
This legislation does not amend any existing Federal
statute.
[all]